Biotech venture capital funding and initial financing rounds notably declined in the first half of 2025, as highlighted by HSBC and industry analyses, erasing the early-year momentum. Concurrently, private investment in life science tools and diagnostics saw a modest rise in deal numbers but with smaller average deal sizes. Despite macroeconomic challenges and tariff uncertainties, strategic financing rounds continued, including significant Series B and C investments in innovative companies focused on genomics and diagnostics platforms.